


COMPANY OVERVIEW

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant *Staph aureus* (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) *Pseudomonas aeruginosa*.



CONTRAFECT CORPORATION

28 Wells Avenue
3rd Floor
Yonkers, NY 10701
US

RECENT NEWS

ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA

Oct 2 2019, 7:00 AM EDT

ContraFect to Host Development Update Call and Webcast on October 2, 2019

Oct 1 2019, 5:29 PM EDT

ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phase 2 Study at IDWeek 2019

Sep 26 2019, 7:00 AM EDT

STOCK OVERVIEW

Symbol	CFRX
Exchange	Nasdaq
Market Cap	23.02m
Last Price	\$0.289865
52-Week Range	\$0.2693 - \$2.6289

10/11/2019 03:59 PM EDT

INVESTOR RELATIONS

Michael Messinger
T: 914-207-2300
mmessinger@contrafect.com

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.